We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Precision BioSciences Inc | NASDAQ:DTIL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.86 | 8.08% | 11.50 | 11.23 | 11.50 | 12.05 | 11.10 | 12.05 | 105,794 | 21:35:01 |
From Nov 2023 to May 2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.
Presentation Details:
Title: Precision Biosciences' PBGENE-HBV Program: A potentially curative strategy to eliminate cccDNA and inactivate integrated HBV DNA through gene editing Presenters: Jeff Smith, Co-Founder and Chief Research Officer, Precision BioSciences; Emily Harrison, HBV Research Lead, Precision BioSciences Date and Time: Tuesday, December 5, 2023, 11:55 AM – 12:10 PM MST Location: Hacienda Del Mar Main Presentation Venue
Title: “Preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B: a potentially curative strategy” Poster Number: Poster #42 Presenter: Emily Harrison, HBV Research Lead, Precision BioSciences Date and Time: Tuesday, December 5, 2023, 2:30 PM – 4:00 PM MST Location: Hacienda Del Mar Poster Session Venue
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231130882274/en/
Investor and Media Contact: Mei Burris Senior Director of Finance and Corporate Controller Mei.Burris@precisionbiosciences.com
1 Year Precision BioSciences Chart |
1 Month Precision BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
